<DOC>
	<DOCNO>NCT02221869</DOCNO>
	<brief_summary>The purpose trial ass efficacy safety Xyrem pediatrics subject narcolepsy include cataplexy .</brief_summary>
	<brief_title>A Multicenter Study Efficacy Safety Xyrem With Open- Label Pharmacokinetic Evaluation Safety Extension Pediatric Subjects With Narcolepsy With Cataplexy</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>1 . Male female subject age 716 year Visit 2 subject Xyrem study entry Visit 1.1 Xyremna√Øve subject ( ensure subject &lt; 18 year age end study ) 2 . Have primary diagnosis narcolepsy cataplexy meet International Classification Sleep Disorders ( ICSD ) 2 ICSD3 criterion , whichever effect time diagnosis , permission Medical Monitor , complete Multiple Sleep Latency Test ( MSLT ) Screening confirm diagnosis Type 1 narcolepsy ICSD3 criterion ( i.e. , subject meet ICSD3 criterion Type 1 narcolepsy ) 3 . Have give documented assent indicate he/she aware investigational nature study require procedure restriction participation protocolrelated activity 4 . Have parent ( ) /guardian ( ) give informed consent his/her/their child 's participation study 5 . Be willing spend require number night ( 2 3 ) sleep laboratory PSG evaluations 6 . If currently treat Xyrem , must take unchanged dos ( twice nightly dose high 9 g/night ) Xyrem , stimulant , applicable , treatment narcolepsy symptom least 2 month prior screen In addition inclusion criterion , subject participate PK evaluation must meet follow inclusion criterion : 7 . Be willing spend 2 additional night clinic PK evaluation 1 . Inability understand assent follow study instruction reason , opinion Investigator 2 . Parent ( ) guardian ( ) unable comply requirement study reason , opinion Investigator 3 . Other document clinically significant condition ( include unstable medical condition , chronic disease narcolepsy cataplexy , history presence another neurological disorder ) might affect subject 's safety and/or interfere conduct study opinion Investigator 4 . Treatment benzodiazepine , nonbenzodiazepine anxiolytics/ hypnotics/sedatives , neuroleptic , opioids , barbiturate , diclofenac , valproate , phenytoin , ethosuximide within 2 week prior enrollment ( discontinuation purpose study enrollment permit consider safe Investigator approve Medical Monitor ) 5 . Treatment medication anticataplectic effect ( e.g. , serotoninnorepinephrine reuptake inhibitor [ SNRIs ] , selective serotonin reuptake inhibitor [ SSRIs ] , tricyclic antidepressant [ TCAs ] ) within 1 month Screening 6 . Unsafe subject receive placebo treatment 2 week , opinion Investigator In addition exclusion criterion , subject participate PK evaluation must demonstrate following :</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>